ICU Medical (NASDAQ:ICUI) Releases FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.750-8.450 for the period, compared to the consensus earnings per share estimate of 7.740. The company issued revenue guidance of -.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler dropped their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a report on Thursday. KeyCorp cut their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a report on Monday, April 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $169.00.

ICU Medical Stock Up 2.8%

Shares of NASDAQ:ICUI traded up $3.50 during trading on Friday, hitting $126.57. 290,454 shares of the company were exchanged, compared to its average volume of 275,650. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 6,332.37, a P/E/G ratio of 1.72 and a beta of 0.74. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The firm has a fifty day moving average price of $128.93 and a two-hundred day moving average price of $138.35. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.23. The company had revenue of $535.94 million for the quarter, compared to analyst estimates of $541.20 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical’s revenue for the quarter was down 14.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.11 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, research analysts anticipate that ICU Medical will post 6.31 earnings per share for the current fiscal year.

Trending Headlines about ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q1 results beat expectations — ICU reported EPS of $1.97 vs. consensus ~$1.78 and revenue of ~$525.8M that beat estimates. Stronger-than-expected EPS drove immediate bullish sentiment. ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: FY?2026 EPS guidance raised/confirmed to a range of 7.750–8.450, slightly above the sell?side consensus — guidance that roughly meets or edges past expectations supports the upbeat analyst reactions. ICU Medical Announces First Quarter 2026 Results
• Positive Sentiment: Analyst actions add momentum — Jefferies upgraded ICUI to “strong-buy” and Piper Sandler reaffirmed a buy rating, which can drive buying interest from institutional and momentum traders. Jefferies Upgrade / Coverage Note Piper Sandler Reaffirms Buy
• Neutral Sentiment: Options activity shows elevated implied volatility — surging IV indicates traders expect bigger near?term moves (could amplify upside or downside volatility). Watch option skew and volume for directional conviction. Implied Volatility Surging for ICU Medical Stock Options
• Neutral Sentiment: Management commentary and slides available — the earnings call transcript and presentation provide detail on drivers (costs, mix, timing) and should inform whether beats are sustainable. Investors should review the call for margin and order?book color. Q1 2026 Earnings Call Transcript Q1 Results Presentation
• Negative Sentiment: Top-line weakness and thin margins remain a concern — revenue was down double digits year?over?year (~12–14% depending on the report) and reported net margin is near zero, which raises questions about sustainability of earnings if volumes don’t recover. This pressure could limit upside without clear signs of recovery. ICU Medical: Q1 Earnings Snapshot

Institutional Trading of ICU Medical

Hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new stake in ICU Medical in the second quarter valued at about $177,000. O Shaughnessy Asset Management LLC acquired a new position in ICU Medical during the 4th quarter worth approximately $203,000. Panagora Asset Management Inc. bought a new position in shares of ICU Medical in the 4th quarter valued at $205,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $216,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.